Literature DB >> 7675241

Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.

R A Maricle1, J G Nutt, R J Valentine, J H Carter.   

Abstract

We investigated the effect of levodopa on mood and anxiety in eight Parkinson's disease patients with motor fluctuations. Each patient received 0.0-, 0.5-, and 1.0-mg/kg/hr levodopa infusions in randomly assigned order under double-blind conditions on consecutive days. Mood elevation and anxiety reduction based on half-hourly patient rating and a corresponding increase in tapping speed occurred with active drug infusion but not placebo infusion. The effects were dose related. The higher-dose infusion rate produced more rapid onset, greater magnitude, and longer duration of response. We conclude that mood and anxiety fluctuations related to levodopa dosing are robust pharmacologic, and not placebo, effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675241     DOI: 10.1212/wnl.45.9.1757

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 3.  Recognition and management of neuropsychiatric complications in Parkinson's disease.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  CMAJ       Date:  2006-12-05       Impact factor: 8.262

4.  Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety.

Authors:  Anne S Berry; Robert L White; Daniella J Furman; Jenna R Naskolnakorn; Vyoma D Shah; Mark D'Esposito; William J Jagust
Journal:  J Neurosci       Date:  2019-02-08       Impact factor: 6.167

5.  Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.

Authors:  Jacob Taylor; William S Anderson; Jason Brandt; Zoltan Mari; Gregory M Pontone
Journal:  Am J Geriatr Psychiatry       Date:  2016-09-03       Impact factor: 4.105

6.  A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Authors:  Ruth B Schneider; Peggy Auinger; Christopher G Tarolli; Julia Iourinets; María Cristina Gil-Díaz; Irene H Richard
Journal:  Parkinsonism Relat Disord       Date:  2020-10-13       Impact factor: 4.891

Review 7.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 8.  Neuropsychiatric symptoms in Parkinson's disease.

Authors:  Dag Aarsland; Laura Marsh; Anette Schrag
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

Review 9.  Parkinson's disease and anxiety.

Authors:  K Walsh; G Bennett
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

10.  Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease.

Authors:  A Funkiewiez; C Ardouin; E Caputo; P Krack; V Fraix; H Klinger; S Chabardes; K Foote; A-L Benabid; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.